Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Haleon PLC A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.	United Kingdom	HLN
Halychpharm A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.	Ukraine	GFARM
HANALL BIOPHARMA CO.,LTD Develops innovative medicines for chronic diseases through antibody and small molecule research.	South Korea	009420
Hana Pharm. Co., Ltd. Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.	South Korea	293480
Hanmi Pharm. Co., Ltd. Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.	South Korea	128940
Hansa Biopharma Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.	Sweden	HNSA
Harmony Biosciences Holdings, Inc. Develops innovative therapies for rare neurological diseases, focusing on conditions like narcolepsy.	United States of America	HRMY
HARROW, INC. Develops branded ophthalmic therapies and custom compounded solutions for North American eyecare.	United States of America	HROW
HCW Biologics Inc. Developing novel immunotherapies to treat aging-related chronic inflammation.	United States of America	HCWB
HEALIOS K.K. Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.	Japan	4593